{
      "Rank": 1,
      "Acronym": [],
      "AgreementOtherDetails": [],
      "AgreementPISponsorEmployee": [],
      "AgreementRestrictionType": [],
      "AgreementRestrictiveAgreement": [],
      "ArmGroupDescription": [
            "Placebo will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes.",
            "Mesenchymal Precursor Cells (MPCs), either 1.0 or 2.0 million cells/kg, will be delivered in 100 mL normal saline administered intravenously over approximately 45 minutes."
      ],
      "ArmGroupInterventionName": [
            "Drug: Allogeneic Mesenchymal Precursor Cells",
            "Drug: Normal Saline"
      ],
      "ArmGroupLabel": [
            "Normal Saline Placebo",
            "Allogeneic Mesenchymal Precursor Cells"
      ],
      "ArmGroupType": [
            "Placebo Comparator",
            "Active Comparator"
      ],
      "AvailIPDComment": [],
      "AvailIPDId": [],
      "AvailIPDType": [],
      "AvailIPDURL": [],
      "BaselineCategoryTitle": [],
      "BaselineClassDenomCountGroupId": [],
      "NCTId": [
            "NCT01851070"
      ],
      "BaselineClassDenomCountValue": [],
      "BaselineClassDenomUnits": [],
      "BaselineClassTitle": [],
      "BaselineDenomCountGroupId": [],
      "BaselineDenomCountValue": [],
      "BaselineDenomUnits": [],
      "BaselineGroupDescription": [],
      "BaselineGroupId": [],
      "BaselineGroupTitle": [],
      "BaselineMeasureCalculatePct": [],
      "BaselineMeasureDenomCountGroupId": [],
      "BaselineMeasureDenomCountValue": [],
      "BaselineMeasureDenomUnits": [],
      "BaselineMeasureDenomUnitsSelected": [],
      "BaselineMeasureDescription": [],
      "BaselineMeasureDispersionType": [],
      "BaselineMeasureParamType": [],
      "BaselineMeasurePopulationDescription": [],
      "BaselineMeasureTitle": [],
      "BaselineMeasureUnitOfMeasure": [],
      "BaselineMeasurementComment": [],
      "BaselineMeasurementGroupId": [],
      "BaselineMeasurementLowerLimit": [],
      "BaselineMeasurementSpread": [],
      "BaselineMeasurementUpperLimit": [],
      "BaselineMeasurementValue": [],
      "BaselinePopulationDescription": [],
      "BaselineTypeUnitsAnalyzed": [],
      "BioSpecDescription": [],
      "BioSpecRetention": [],
      "BriefSummary": [
            "Study is a double-blind, randomized, placebo controlled, dose escalating study. The primary objective of this study is to evaluate the safety, tolerability and feasibility of a single intravenous infusion of allogeneic mesenchymal precursor cells (MPCs) compared to placebo at 12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (RA) who have received methotrexate +/- other DMARDs for at least 6 months prior to screening and who have had an incomplete response to at least one TNF-alpha inhibitor."
      ],
      "BriefTitle": [
            "A Multi-center Study a Single IV Infusion of Allogeneic MPCs in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNF\u03b1 Inhibitor"
      ],
      "CentralContactEMail": [],
      "CentralContactName": [],
      "CentralContactPhone": [],
      "CentralContactPhoneExt": [],
      "CentralContactRole": [],
      "CollaboratorClass": [
            "INDUSTRY"
      ],
      "CollaboratorName": [
            "PPD"
      ],
      "CompletionDate": [
            "March 2017"
      ],
      "CompletionDateType": [
            "Actual"
      ],
      "Condition": [
            "Rheumatoid Arthritis"
      ],
      "ConditionAncestorId": [
            "D000007592",
            "D000009140",
            "D000012216",
            "D000003240",
            "D000001327",
            "D000007154"
      ],
      "ConditionAncestorTerm": [
            "Joint Diseases",
            "Musculoskeletal Diseases",
            "Rheumatic Diseases",
            "Connective Tissue Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases"
      ],
      "ConditionBrowseBranchAbbrev": [
            "BC05",
            "All",
            "BC17",
            "BC20"
      ],
      "ConditionBrowseBranchName": [
            "Musculoskeletal Diseases",
            "All Conditions",
            "Skin and Connective Tissue Diseases",
            "Immune System Diseases"
      ],
      "ConditionBrowseLeafAsFound": [
            "Arthritis",
            "Rheumatoid Arthritis"
      ],
      "ConditionBrowseLeafId": [
            "M3628",
            "M3632",
            "M9773",
            "M11249",
            "M14197",
            "M5475",
            "M5616",
            "M3781",
            "M9352"
      ],
      "ConditionBrowseLeafName": [
            "Arthritis",
            "Arthritis, Rheumatoid",
            "Joint Diseases",
            "Musculoskeletal Diseases",
            "Rheumatic Diseases",
            "Collagen Diseases",
            "Connective Tissue Diseases",
            "Autoimmune Diseases",
            "Immune System Diseases"
      ],
      "ConditionBrowseLeafRelevance": [
            "high",
            "high",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low",
            "low"
      ],
      "ConditionMeshId": [
            "D000001168",
            "D000001172"
      ],
      "ConditionMeshTerm": [
            "Arthritis",
            "Arthritis, Rheumatoid"
      ],
      "DelayedPosting": [],
      "DesignAllocation": [
            "Randomized"
      ],
      "DesignInterventionModel": [
            "Parallel Assignment"
      ],
      "DesignInterventionModelDescription": [],
      "DesignMasking": [
            "Triple"
      ],
      "DesignMaskingDescription": [],
      "DesignObservationalModel": [],
      "DesignPrimaryPurpose": [
            "Treatment"
      ],
      "DesignTimePerspective": [],
      "DesignWhoMasked": [
            "Participant",
            "Investigator",
            "Outcomes Assessor"
      ],
      "DetailedDescription": [],
      "DispFirstPostDate": [],
      "DispFirstPostDateType": [],
      "DispFirstSubmitDate": [],
      "DispFirstSubmitQCDate": [],
      "EligibilityCriteria": [
            "Inclusion Criteria:\n\nMales and Females ages 18-80 years old\nActive rheumatoid arthritis (RA) disease as per 2010 ACR/EULAR classification criteria for the diagnosis of RA.\nMust be positive for rheumatoid factor and/or anti-cyclic citrullinated peptide (anti-CCP3) but without extra-articular disease or functional limitation\n\nPatient with active RA defined as:\n\n\u2265 4 tender joint count (TJC) 28 joint count at screening and\n\u2265 4 swollen joint count (SJC) count 28 joint count at screening\nESR \u2265 28 mm/hr or hsCRP >2.0 mg/L\nPatient has been taking MTX for at least 4 months with dose and route of administration stable for at least 8 weeks prior to screening\nPatient has had an inadequate response to at least one TNF\u03b1 inhibitor with last dose at least 6 weeks prior to screening\nUse of oral DMARD (sulfasalazine, hydroxychloroquine, chloroquine and leflunomide) is permitted but must be stable for at least 3 months prior to screening\n\nExclusion Criteria:\n\nPregnant women or women who are breastfeeding.\nOther investigational therapy received within 8 weeks or five half-lives (whichever is longer) prior to Screening (except as in exclusion #13).\nKnown or suspected alcohol or drug abuse within three years preceding Screening.\nAutoimmune disease other than RA (such as systemic lupus erythematosus (SLE), mixed connective tissue disease, scleroderma, polymyositis/dermatomyositis, vasculitis)\nHistory of or current inflammatory joint disease other than RA (such as tophaceous gout, reactive arthritis, psoriatic arthritis, ankylosing spondylitis or other spondyloarthropathy, Lyme disease). Patients primarily diagnosed with osteoarthritis are excluded.\nBedridden or confined to a wheelchair or patients with > 3 arthroplasties due to RA.\nHistory of diagnosed and/or treated malignancy with no evidence of recurrence in past 5 years\nSurgical procedures planned to occur during the trial (these patients may be rescreened following completion of and recovery from the surgical procedure).\nUse of TNF\u03b1 inhibitor for treatment of RA at time of screening or within the 6 weeks prior to screening.\nPrior use of biologic agent for treatment of RA within 6 weeks prior to screening"
      ],
      "EnrollmentCount": [
            "48"
      ],
      "EnrollmentType": [
            "Actual"
      ],
      "EventGroupDeathsNumAffected": [],
      "EventGroupDeathsNumAtRisk": [],
      "EventGroupDescription": [],
      "EventGroupId": [],
      "EventGroupOtherNumAffected": [],
      "EventGroupOtherNumAtRisk": [],
      "EventGroupSeriousNumAffected": [],
      "EventGroupSeriousNumAtRisk": [],
      "EventGroupTitle": [],
      "EventsDescription": [],
      "EventsFrequencyThreshold": [],
      "EventsTimeFrame": [],
      "ExpAccTypeIndividual": [],
      "ExpAccTypeIntermediate": [],
      "ExpAccTypeTreatment": [],
      "ExpandedAccessNCTId": [],
      "ExpandedAccessStatusForNCTId": [],
      "FDAAA801Violation": [],
      "FlowAchievementComment": [],
      "FlowAchievementGroupId": [],
      "FlowAchievementNumSubjects": [],
      "FlowAchievementNumUnits": [],
      "FlowDropWithdrawComment": [],
      "FlowDropWithdrawType": [],
      "FlowGroupDescription": [],
      "FlowGroupId": [],
      "FlowGroupTitle": [],
      "FlowMilestoneComment": [],
      "FlowMilestoneType": [],
      "FlowPeriodTitle": [],
      "FlowPreAssignmentDetails": [],
      "FlowReasonComment": [],
      "FlowReasonGroupId": [],
      "FlowReasonNumSubjects": [],
      "FlowReasonNumUnits": [],
      "FlowRecruitmentDetails": [],
      "FlowTypeUnitsAnalyzed": [],
      "Gender": [
            "All"
      ],
      "GenderBased": [],
      "GenderDescription": [],
      "HasExpandedAccess": [
            "No"
      ],
      "HealthyVolunteers": [
            "No"
      ],
      "IPDSharing": [],
      "IPDSharingAccessCriteria": [],
      "IPDSharingDescription": [],
      "IPDSharingInfoType": [],
      "IPDSharingTimeFrame": [],
      "IPDSharingURL": [],
      "InterventionAncestorId": [],
      "InterventionAncestorTerm": [],
      "InterventionArmGroupLabel": [
            "Normal Saline Placebo",
            "Allogeneic Mesenchymal Precursor Cells"
      ],
      "InterventionBrowseBranchAbbrev": [],
      "InterventionBrowseBranchName": [],
      "InterventionBrowseLeafAsFound": [],
      "InterventionBrowseLeafId": [],
      "InterventionBrowseLeafName": [],
      "InterventionBrowseLeafRelevance": [],
      "InterventionDescription": [],
      "InterventionMeshId": [],
      "InterventionMeshTerm": [],
      "InterventionName": [
            "Allogeneic Mesenchymal Precursor Cells",
            "Normal Saline"
      ],
      "InterventionOtherName": [],
      "InterventionType": [
            "Drug",
            "Drug"
      ],
      "IsFDARegulatedDevice": [],
      "IsFDARegulatedDrug": [],
      "IsPPSD": [],
      "IsUSExport": [],
      "IsUnapprovedDevice": [],
      "Keyword": [],
      "LargeDocDate": [],
      "LargeDocFilename": [],
      "LargeDocHasICF": [],
      "LargeDocHasProtocol": [],
      "LargeDocHasSAP": [],
      "LargeDocLabel": [],
      "LargeDocTypeAbbrev": [],
      "LargeDocUploadDate": [],
      "LastKnownStatus": [],
      "LastUpdatePostDate": [
            "June 26, 2020"
      ],
      "LastUpdatePostDateType": [
            "Actual"
      ],
      "LastUpdateSubmitDate": [
            "June 25, 2020"
      ],
      "LeadSponsorClass": [
            "INDUSTRY"
      ],
      "LeadSponsorName": [
            "Mesoblast, Ltd."
      ],
      "LimitationsAndCaveatsDescription": [],
      "LocationCity": [
            "Anniston",
            "Gilbert",
            "El Cajon",
            "Los Angeles",
            "Upland",
            "Ocala",
            "Palm Harbor",
            "Sarasota",
            "Tampa",
            "Baltimore",
            "Frederick",
            "Worcester",
            "Rochester",
            "Fair Lawn",
            "Charlotte",
            "Oklahoma City",
            "Pittsburgh",
            "Jackson",
            "Houston",
            "San Antonio",
            "Camperdown",
            "Hobart",
            "Malvern"
      ],
      "LocationContactEMail": [],
      "LocationContactName": [],
      "LocationContactPhone": [],
      "LocationContactPhoneExt": [],
      "LocationContactRole": [],
      "LocationCountry": [
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "United States",
            "Australia",
            "Australia",
            "Australia"
      ],
      "LocationFacility": [
            "Pinnacle Research Group",
            "Arthrocare Arthritis Care and Research PC",
            "Triwest Research Associates",
            "UCLA",
            "Inland Rheumatology Clinical Trials Incorporated",
            "Ocala Rheumatology Research Center",
            "Arthritis Center",
            "Sarasota Arthritis Research Center",
            "McIlwain Medical Group",
            "JHU Arthritis Center Baltimore",
            "Arthritis Treatment Center",
            "Reliant Medical Group",
            "Mayo Clinic",
            "Office of Ramesh C. Gupta, MD",
            "DJL Clinical Research",
            "Health Research of Oklahoma",
            "University of Pittsburgh",
            "West Tennessee Research Institute",
            "Accurate Clinical Research",
            "Texas Arthritis Research Center",
            "Royal Prince Alfred Hospital",
            "Southern Clinical Research Pty Ltd",
            "Emeritus Research"
      ],
      "LocationState": [
            "Alabama",
            "Arizona",
            "California",
            "California",
            "California",
            "Florida",
            "Florida",
            "Florida",
            "Florida",
            "Maryland",
            "Maryland",
            "Massachusetts",
            "Minnesota",
            "New Jersey",
            "North Carolina",
            "Oklahoma",
            "Pennsylvania",
            "Tennessee",
            "Texas",
            "Texas",
            "New South Wales",
            "Tasmania",
            "Victoria"
      ],
      "LocationStatus": [],
      "LocationZip": [
            "36207",
            "85234",
            "92020",
            "90025",
            "91786",
            "34474",
            "34684",
            "34239",
            "33614",
            "21224",
            "21702",
            "01605",
            "55905",
            "07410",
            "28210",
            "73102",
            "15261",
            "38305",
            "77034",
            "78217",
            "2050",
            "7000",
            "3145"
      ],
      "MaximumAge": [
            "80 Years"
      ],
      "MinimumAge": [
            "18 Years"
      ],
      "NCTIdAlias": [],
      "OfficialTitle": [
            "A Double-blind, Randomized, Placebo-controlled, Dose-escalation, Multi-center Study a Single Intravenous Infusion of Allogeneic Mesenchymal Precursor Cells (MPCs) in Patients With Rheumatoid Arthritis and Incomplete Response to at Least One TNF\u03b1 Inhibitor"
      ],
      "OrgClass": [
            "INDUSTRY"
      ],
      "OrgFullName": [
            "Mesoblast, Ltd."
      ],
      "OrgStudyId": [
            "MSB-RA001"
      ],
      "OrgStudyIdDomain": [],
      "OrgStudyIdLink": [],
      "OrgStudyIdType": [],
      "OtherEventAssessmentType": [],
      "OtherEventNotes": [],
      "OtherEventOrganSystem": [],
      "OtherEventSourceVocabulary": [],
      "OtherEventStatsGroupId": [],
      "OtherEventStatsNumAffected": [],
      "OtherEventStatsNumAtRisk": [],
      "OtherEventStatsNumEvents": [],
      "OtherEventTerm": [],
      "OtherOutcomeDescription": [],
      "OtherOutcomeMeasure": [],
      "OtherOutcomeTimeFrame": [],
      "OutcomeAnalysisCILowerLimit": [],
      "OutcomeAnalysisCILowerLimitComment": [],
      "OutcomeAnalysisCINumSides": [],
      "OutcomeAnalysisCIPctValue": [],
      "OutcomeAnalysisCIUpperLimit": [],
      "OutcomeAnalysisCIUpperLimitComment": [],
      "OutcomeAnalysisDispersionType": [],
      "OutcomeAnalysisDispersionValue": [],
      "OutcomeAnalysisEstimateComment": [],
      "OutcomeAnalysisGroupDescription": [],
      "OutcomeAnalysisGroupId": [],
      "OutcomeAnalysisNonInferiorityComment": [],
      "OutcomeAnalysisNonInferiorityType": [],
      "OutcomeAnalysisOtherAnalysisDescription": [],
      "OutcomeAnalysisPValue": [],
      "OutcomeAnalysisPValueComment": [],
      "OutcomeAnalysisParamType": [],
      "OutcomeAnalysisParamValue": [],
      "OutcomeAnalysisStatisticalComment": [],
      "OutcomeAnalysisStatisticalMethod": [],
      "OutcomeAnalysisTestedNonInferiority": [],
      "OutcomeCategoryTitle": [],
      "OutcomeClassDenomCountGroupId": [],
      "OutcomeClassDenomCountValue": [],
      "OutcomeClassDenomUnits": [],
      "OutcomeClassTitle": [],
      "OutcomeDenomCountGroupId": [],
      "OutcomeDenomCountValue": [],
      "OutcomeDenomUnits": [],
      "OutcomeGroupDescription": [],
      "OutcomeGroupId": [],
      "OutcomeGroupTitle": [],
      "OutcomeMeasureAnticipatedPostingDate": [],
      "OutcomeMeasureCalculatePct": [],
      "OutcomeMeasureDenomUnitsSelected": [],
      "OutcomeMeasureDescription": [],
      "OutcomeMeasureDispersionType": [],
      "OutcomeMeasureParamType": [],
      "OutcomeMeasurePopulationDescription": [],
      "OutcomeMeasureReportingStatus": [],
      "OutcomeMeasureTimeFrame": [],
      "OutcomeMeasureTitle": [],
      "OutcomeMeasureType": [],
      "OutcomeMeasureTypeUnitsAnalyzed": [],
      "OutcomeMeasureUnitOfMeasure": [],
      "OutcomeMeasurementComment": [],
      "OutcomeMeasurementGroupId": [],
      "OutcomeMeasurementLowerLimit": [],
      "OutcomeMeasurementSpread": [],
      "OutcomeMeasurementUpperLimit": [],
      "OutcomeMeasurementValue": [],
      "OverallOfficialAffiliation": [
            "Mesoblast, Ltd."
      ],
      "OverallOfficialName": [
            "Donna Skerrett, MD, MS"
      ],
      "OverallOfficialRole": [
            "Study Director"
      ],
      "OverallStatus": [
            "Completed"
      ],
      "OversightHasDMC": [
            "Yes"
      ],
      "PatientRegistry": [],
      "Phase": [
            "Phase 2"
      ],
      "PointOfContactEMail": [],
      "PointOfContactOrganization": [],
      "PointOfContactPhone": [],
      "PointOfContactPhoneExt": [],
      "PointOfContactTitle": [],
      "PrimaryCompletionDate": [
            "May 2016"
      ],
      "PrimaryCompletionDateType": [
            "Actual"
      ],
      "PrimaryOutcomeDescription": [
            "To evaluate the safety, tolerability and feasibility of a single intravenous (IV) infusion of allogeneic mesenchymal precursor cells (MPCs) compared to placebo at 12 weeks post-infusion in the treatment of patients with active rheumatoid arthritis (RA) who have received methotrexate +/- other oral DMARDs for at least 4 months and who have had an incomplete response to at least one course of a TNF\u03b1 inhibitor.\n\nOverall safety will be based on the overall assessment of AE/SAEs, Vital Signs, Physical Examination, clinical laboratory tests, ECGs and Chest x-ray."
      ],
      "PrimaryOutcomeMeasure": [
            "Evaluation of the safety of a single IV infusion of allogeneic MPCs compared to placebo at 12 weeks post-infusion"
      ],
      "PrimaryOutcomeTimeFrame": [
            "12 weeks post IV Infusion"
      ],
      "ReferenceCitation": [],
      "ReferencePMID": [],
      "ReferenceType": [],
      "RemovedCountry": [],
      "ResponsiblePartyInvestigatorAffiliation": [],
      "ResponsiblePartyInvestigatorFullName": [],
      "ResponsiblePartyInvestigatorTitle": [],
      "ResponsiblePartyOldNameTitle": [],
      "ResponsiblePartyOldOrganization": [],
      "ResponsiblePartyType": [
            "Sponsor"
      ],
      "ResultsFirstPostDate": [],
      "ResultsFirstPostDateType": [],
      "ResultsFirstPostedQCCommentsDate": [],
      "ResultsFirstPostedQCCommentsDateType": [],
      "ResultsFirstSubmitDate": [],
      "ResultsFirstSubmitQCDate": [],
      "RetractionPMID": [],
      "RetractionSource": [],
      "SamplingMethod": [],
      "SecondaryId": [],
      "SecondaryIdDomain": [],
      "SecondaryIdLink": [],
      "SecondaryIdType": [],
      "SecondaryOutcomeDescription": [
            "To assess the efficacy of a single intravenous infusion of allogeneic MPCs compared with placebo at 12 weeks post-infusion with MPCs or placebo in the treatment of patients with active RA who have received methotrexate +/- other DMARDs for at least 4 months and who have had an incomplete response to least one TNF\u03b1 inhibitor.",
            "To evaluate the long-term efficacy and safety of allogeneic MPCs over the entire study duration in the treatment of patients with active RA who have received methotrexate +/- other DMARDs for at least 4 months and who have had an incomplete response to at least one TNF\u03b1 inhibitor\n\nSafety will be assessed according to the following:\n\nAdverse events/serious adverse events (\"primary endpoint\")\nVital signs\nPhysical examination\nClinical laboratory tests\nElectrocardiogram\nChest x-ray (CXR)\n\nEfficacy will be assessed according to the following:\n\nACR20/50/70\nDAS28 (mean changes from baseline as measured by using hsCRP and ESR)\nMean changes from baseline in all components of the ACR core response criteria\nRemissions (as defined in the 2011 Joint Statement of the American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR)\nJoint erosion of hands and wrists assessed via x-ray\n\nPatient-reported outcomes\n\nSF36v2\nHAQ_DI"
      ],
      "SecondaryOutcomeMeasure": [
            "Evaluation of the efficacy of a single intravenous infusion of allogeneic MPCs compared with placebo at 12 weeks post-infusion with MPCs or placebo in the treatment of patients with active RA",
            "Evaluation of long-term safety and efficacy of a singly IV infusion of allogeneic MPCs in patients with active RA"
      ],
      "SecondaryOutcomeTimeFrame": [
            "12 weeks post IV infusion with MPCs",
            "52 weeks post IV Infusion"
      ],
      "SeeAlsoLinkLabel": [],
      "SeeAlsoLinkURL": [],
      "SeriousEventAssessmentType": [],
      "SeriousEventNotes": [],
      "SeriousEventOrganSystem": [],
      "SeriousEventSourceVocabulary": [],
      "SeriousEventStatsGroupId": [],
      "SeriousEventStatsNumAffected": [],
      "SeriousEventStatsNumAtRisk": [],
      "SeriousEventStatsNumEvents": [],
      "SeriousEventTerm": [],
      "StartDate": [
            "July 2013"
      ],
      "StartDateType": [
            "Actual"
      ],
      "StatusVerifiedDate": [
            "June 2020"
      ],
      "StdAge": [
            "Adult",
            "Older Adult"
      ],
      "StudyFirstPostDate": [
            "May 10, 2013"
      ],
      "StudyFirstPostDateType": [
            "Estimate"
      ],
      "StudyFirstSubmitDate": [
            "April 19, 2013"
      ],
      "StudyFirstSubmitQCDate": [
            "May 9, 2013"
      ],
      "StudyPopulation": [],
      "StudyType": [
            "Interventional"
      ],
      "SubmissionMCPReleaseN": [],
      "SubmissionReleaseDate": [],
      "SubmissionResetDate": [],
      "SubmissionUnreleaseDate": [],
      "TargetDuration": [],
      "UnpostedEventDate": [],
      "UnpostedEventType": [],
      "UnpostedResponsibleParty": [],
      "VersionHolder": [
            "October 07, 2022"
      ],
      "WhyStopped": []
}